STE Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 12.66% compared to Steris PLC's net margin of 12.41%. Steris PLC's return on equity of 7.27% beat Boston Scientific's return on equity of 8.96%.

Steris PLC has a consensus price target of $250.13, signalling upside risk potential of 13.48%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 14.83%. Given that Boston Scientific has higher upside potential than Steris PLC, analysts believe Boston Scientific is more attractive than Steris PLC.

Steris PLC has a beta of 0.919, which suggesting that the stock is 8.088% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1.01%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Steris PLC pays 53.03% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.4B, which are smaller than Boston Scientific quarterly revenues of $4.6B. Steris PLC's net income of $173.5M is lower than Boston Scientific's net income of $566M. Notably, Steris PLC's price-to-earnings ratio is 46.80x while Boston Scientific's PE ratio is 80.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.05x versus 8.93x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

NeuroOne Medical Technologies has a net margin of 12.66% compared to Steris PLC's net margin of 54.53%. Steris PLC's return on equity of 7.27% beat NeuroOne Medical Technologies's return on equity of -238.93%.

Steris PLC has a consensus price target of $250.13, signalling upside risk potential of 13.48%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of -- which suggests that it could grow by 95.12%. Given that NeuroOne Medical Technologies has higher upside potential than Steris PLC, analysts believe NeuroOne Medical Technologies is more attractive than Steris PLC.

Steris PLC has a beta of 0.919, which suggesting that the stock is 8.088% less volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.118%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1.01%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Steris PLC pays 53.03% of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.4B, which are larger than NeuroOne Medical Technologies quarterly revenues of $3.3M. Steris PLC's net income of $173.5M is higher than NeuroOne Medical Technologies's net income of $1.8M. Notably, Steris PLC's price-to-earnings ratio is 46.80x while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.05x versus 5.08x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of 12.66% compared to Steris PLC's net margin of -211%. Steris PLC's return on equity of 7.27% beat Nutriband's return on equity of -69.58%.

Steris PLC has a consensus price target of $250.13, signalling upside risk potential of 13.48%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 93.17%. Given that Nutriband has higher upside potential than Steris PLC, analysts believe Nutriband is more attractive than Steris PLC.

Steris PLC has a beta of 0.919, which suggesting that the stock is 8.088% less volatile than S&P 500. In comparison Nutriband has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.457%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1.01%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Steris PLC pays 53.03% of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.4B, which are larger than Nutriband quarterly revenues of $645.8K. Steris PLC's net income of $173.5M is higher than Nutriband's net income of -$1.4M. Notably, Steris PLC's price-to-earnings ratio is 46.80x while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.05x versus 32.99x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of 12.66% compared to Steris PLC's net margin of 11.84%. Steris PLC's return on equity of 7.27% beat Zimmer Biomet Holdings's return on equity of 7.21%.

Steris PLC has a consensus price target of $250.13, signalling upside risk potential of 13.48%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $121.85 which suggests that it could grow by 10.04%. Given that Steris PLC has higher upside potential than Zimmer Biomet Holdings, analysts believe Steris PLC is more attractive than Zimmer Biomet Holdings.

Steris PLC has a beta of 0.919, which suggesting that the stock is 8.088% less volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.696%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1.01%. Zimmer Biomet Holdings offers a yield of 0.87% to investors and pays a quarterly dividend of $0.24 per share. Steris PLC pays 53.03% of its earnings as a dividend. Zimmer Biomet Holdings pays out 21.69% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.4B, which are smaller than Zimmer Biomet Holdings quarterly revenues of $2B. Steris PLC's net income of $173.5M is lower than Zimmer Biomet Holdings's net income of $239.5M. Notably, Steris PLC's price-to-earnings ratio is 46.80x while Zimmer Biomet Holdings's PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.05x versus 2.94x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.